Parents Against Psych Abuse
ADHD Does Not Exist: The Truth About Attention Deficit and Hyperactivity Disorder, Richard Saul, M.D., February 18, 2014
Saving Normal: An Insider's Revolt Against Out-of-Control Psychiatric Diagnosis, DSM-5, Big Pharma, and the Medicalization of Ordinary Life, Allen Frances, M.D., May 14, 2013
The Book of Woe: The DSM and the Unmaking of Psychiatry, Gary Greenberg, May 2, 2013
Mad Science: Psychiatric Coercion, Diagnosis, and Drugs, Stuart A. Kirk, Tomi Gomory and David Cohen, April 4, 2013
Psychiatryland: How to Protect Yourself from Pill-Pushing Psychiatrists and Develop a Personal Plan for Optimal Mental Health, (Tampa Bay area psychiatrist) Phillip Sinaikin, M.D., Sept. 10, 2010
The ADHD Fraud: How Psychiatry Makes "Patients" Out of Normal Children, Fred A. Baughman, Jr., M.D., June 30, 2006
The Selling of Attention Deficit Disorder, New York Times, December 14, 2013
Alan Schwarz links soaring diagnoses of Attention Deficit Disorder with a 20-year drug marketing campaign funded by Big Pharma to expand their addressable market. Schwarz examines Big Pharma's false advertising and marketing of ADHD drugs to doctors, schools, parents and children; their funding of �scientific� studies to increase diagnosis and medication of the condition; their financial support of advocacy groups such as CHADD to expand their market and promote their drugs; and their payments to doctors who promote ADHD drugs to other doctors. In addition to the over-diagnosis and over-medication of childhood ADHD, Schwarz looks at Big Pharma's more recent campaign to increase the diagnosis and medication of adult ADHD, a potentially larger, long-term market if people can be sold on the idea of being medicated for life.
Revised Psychiatric Manual Faces Mixed Reviews, Wall Street Journal, May 17, 2013
National Institute of Mental Health (NIMH) Director Thomas R. Insel, M.D. and American Psychiatric Association (APA) President-Elect Jeffrey A. Lieberman, M.D.'s hasty clarification of Insel's criticism of the DSM-5, in a joint press release intended to mend the cracking facade, fails to bridge the ever-widening chasm between researchers and clinicians in psychiatry. The meltdown continues...
DSM-5 and RDoC: Shared Interests, Joint Press Release of NIMH Director Thomas R. Insel, M.D. and APA President-Elect Jeffrey A. Lieberman, M.D., May 13, 2013
A day after a USA TODAY article shined the national spotlight on NIMH Director Insel's charges in a blog post that the DSM-5's "weakness is its lack of validity," NIMH Director Insel and APA President-Elect Lieberman attempt to walk back Insel's criticism of the DSM-5 and show solidarity in the face of the growing controversy, credibility gap and legitimacy crisis engulfing psychiatry and psychology. No doubt they got some angry phone calls and emails from greedy Big Pharma lobbyists suffering from a sudden onset of Intermittent Explosive Disorder (IED). Chillax, Fellas, there's a pill for that.
Books blast new version of psychiatry's bible, the DSM, USA TODAY, May 12, 2013
Sharon Jayson's article on Allen Frances, Gary Greenberg and Stuart Kirk et al's respective books critical of the DSM-5 rips the scab off the festering debate over the current state of psychiatry and psychology. While Jayson's main focus is on books critical of the DSM-5 timed to coincide with its release, the real bombshell is when she calls national attention to NIMH Director Insel's blog attack on the validity of the DSM-5, which seemingly adds official weight to these critics' books, and unleashes a chain reaction of damage control on the part of the mental health industry's heads of state. Note: Allen Frances, M.D.'s book probably does not need any more official weight, considering that he chaired the DSM-IV Task Force.
Transforming Diagnosis, NIMH Director Thomas R. Insel, M.D.'s Blog, Apr. 29, 2013
NIMH Director Thomas Insel, M.D. declares, "While DSM has been described as a 'Bible' for the field, it is, at best, a dictionary, creating a set of labels and defining each... The weakness is its lack of validity... DSM diagnoses are based on a consensus about clusters of clinical symptoms, not any objective laboratory measure... Patients with mental disorders deserve better... That is why NIMH will be re-orienting its research away from DSM categories."
More Diagnoses of ADHD Causing Concern, New York Times, Mar. 31, 2013
Alan Schwarz deserves a Pultizer Prize for his reporting, along with Sarah Cohen, in this his third installment in a series of articles focused on the rampant over-diagnosis and over-medication of ADHD. Whereas historically ADHD diagnoses were estimated between 3 to 7 percent of school age children, new data from the Centers for Disease Control and Prevention (CDC) shows the number of diagnoses skyrocketing, with 1 in 5 high school age boys having been diagnosed with ADHD. Schwarz quotes Florida International University professor of psychiatry James Swanson as saying, "There�s no way that one in five high-school boys has A.D.H.D." Swanson warns, "If we start treating children who do not have the disorder with stimulants... some of them are going to end up with abuse and dependence." Schwarz cites IMS Heath data indicating that sales of stimulants used to treat ADHD have more than doubled in the last five years, jumping from $4B per year in 2007 to $9B per year in 2012.
Drowned in a Stream of Prescriptions,
New York Times, Feb. 2, 2013
Alan Schwarz recounts the heart-breaking tragedy of a young man's promising life ended prematurely by an addiction to ADHD medication, and his parents' anguish as they tried in vain to stop professionals from prescribing more medication while their son continued to spiral downward. The article highlights the dangerous trend among college students of abusing Adderall as an academic Performance Enhancing Drug (PED).
Children and Adults with Attention-Deficit/Hyperactivity Disorder (CHADD) is also exposed in the article for what it really is - a Big Pharma
front sponsored advocacy group. The distraught parents whose son killed himself after being over-prescribed Adderall against their wishes find themselves at a CHADD meeting underwritten in part by Shire, manufacturer of the ADHD drugs Adderall, Adderall XR, Daytrana, Vyvanse and Intuniv. Parents attending the CHADD meeting are made to sit through an "hourlong film examining... 'myths' about stimulant medications, with several doctors praising their efficacy and safety. One said they were 'safer than aspirin'..."
This is not the first time concerns have been raised about so-called "parent associations" advocating the use of stimulant medications. As early as 1995, in their annual report, the United Nations (UN) International Narcotics Control Board (INCB) asked U.S. authorities to investigate "whether article 10, paragraph 2, of the 1971 Convention [on Psychotropic Substances], prohibiting the advertisement of controlled substances to the general public, is not being undermined by the activities of 'parent associations' advocating the use of methylphenidate [the active ingredient in the ADHD drugs Ritalin, Concerta, Daytrana, Methylin, Quillivant XR, etc.]."
Attention Disorder or Not, Children Prescribed Pills to Help in School,
New York Times, Oct. 9, 2012
The irony was not lost - just one day before the United States Anti-Doping Agency (USADA) released its reasonsed decision and report stripping Lance Armstrong of seven Tour de France titles due to his use of PEDs, Alan Schwarz penned this article about how kids are being prescribed Adderall for slipping grades whether they have ADHD or not. More recently, controversy erupted during Seattle Seahawks cornerback Richard Sherman's visit to a Surrey, B.C. elementary school where he made the assertion that "about half" of the NFL uses the banned stimulant Adderall. The message to kids: use of PEDs constitutes cheating in sports, but not in academics.